NVCT vs VALN: fair value comparison
Nuvectis Pharma, Inc. and Valneva SE · Updated 2026-10-19
NVCT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. VALN reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, VALN currently ranks higher by quality score.
| NVCT | VALN | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $18.60 | $5.90 |
| 12-month range | $5.65–$28.53 | $4.78–$11.99 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #301 of 301 Healthcare | #299 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | High |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: NVCT fair value analysis · VALN fair value analysis